Maintaining long-term BP control is essential for reducing cardiovascular risk. A Circulation report evaluated the one-year efficacy and safety of a low-dose triple single-pill combination in adults with mild-to-moderate hypertension from Sri Lanka and Nigeria.

Fifty participants entered an open-label extension (OLE) after a 4-week randomized placebo-controlled phase. The mean age was 49 years, and 60% were female. At OLE entry, mean home BP was 129/79 mmHg and mean clinic BP was 131/83 mmHg. Participants began GMRx2 at the ¼ dose, with up-titration to higher strengths if needed. Further escalation included the addition of a telmisartan and amlodipine single-pill combination and, if required, spironolactone to reach a home BP target of <130/80 mmHg.

Home BP declined to 121/78 mmHg at four weeks and remained stable at 120/78 mmHg at week 52. Clinic BP fell to 126/79 mmHg and then to 122/77 mmHg at week 52. At one year, 56% achieved home BP control (<130/80 mmHg), and 88% achieved clinic BP control (<140/90 mmHg). At week 52, 53% remained on GMRx2 ¼ dose, 27% on ½ dose, and 22% on the standard dose. Only three participants required add-on therapy. Tolerability was good, and no participant discontinued treatment because of an adverse event.

These findings show that GMRx2-based therapy supported sustained BP reduction over one year with strong tolerability and minimal need for treatment escalation.